Mental Health DailyResearch. Evidence. Perspective.Published research on semaglutide.
A 2026 review concluded that GLP-1 receptor agonists have plausible stroke biology and modest prevention signals, but current human evidence does not support routine use as acute ischemic st…
Read articleGLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) act on the brain as well as the gut, and a 2026 real-world cohort study from Kamel-Abusalha et al. propensity-matched 118,993 …
Read articleA 2026 target-trial emulation involving 102,361 U.S. veterans with type 2 diabetes found no increased suicidality risk after starting semaglutide vs. sodium-glucose cotransporter-2 inhibitor…
Read articleGLP-1 drugs are usually described as appetite drugs, but a 2026 Nature mouse study mapped a more specific reward circuit: small-molecule GLP-1 receptor agonists suppressed palatable-food int…
Read articleSemaglutide is not close to being an approved cocaine-use-disorder medication, but a 2026 rat study gives the idea a more demanding preclinical test than ordinary self-administration experim…
Read articleA 2026 Scientific Reports paper involving 1,205 participants found that people using GLP-1-style weight-loss medication were judged as less effortful, less moral, less competent, less warm, …
Read articleObesity now affects over 650 million adults globally and is a major risk factor for various chronic diseases including cognitive decline and impairment. Recent evidence shows a link between …
Read article
